OAT (organic anion transporter) 2 [human gene symbol SLC22A7 (SLC is solute carrier)] is a member of the SLC22 family of transport proteins. In the rat, the principal site of expression of OAT2 is the sinusoidal membrane domain of hepatocytes. The particular physiological function of OAT2 in liver has been unresolved so far. In the present paper, we have used the strategy of LC (liquid chromatography)-MS difference shading to search for specific and cross-species substrates of OAT2. Heterologous expression of human and rat OAT2 in HEK (human embryonic kidney)-293 cells stimulated accumulation of the zwitterion trigonelline; subsequently, orotic acid was identified as an excellent and specific substrate of OAT2 from the rat (clearance = 106 μl · min 
INTRODUCTION
The integral membrane protein presently called OAT (organic anion transporter) 2 [human gene symbol SLC22A7 (SLC is solute carrier)] was first spotted with a monoclonal antibody at the sinusoidal membrane domain of rat hepatocytes [1] . Northern blot analysis of several rat tissues with the corresponding cDNA as a probe revealed strong expression in the liver and much weaker expression in the kidney [1, 2] . OAT2 represents a marker for highly differentiated liver cells, since its hepatic transcription starts only at birth [1] ; it is hence, in general, not expressed natively in established cell lines.
OAT2 is a member of the SLC22 family of transport proteins. Injection of cRNA of OAT2 from rat into Xenopus oocytes was reported to promote uptake of several radiolabelled substrates of OAT1 (SLC22A6) like salicylate, PAH (p-aminohippuric acid) and 2-oxoglutarate [2] ; the protein was thus named 'multispecific' OAT type 2. However, subsequent functional studies with OAT2 from human, rat and mouse have yielded inconsistent results on the substrate specificity of this carrier [3] . Most of these studies were based on expression in Xenopus oocytes. Since oocytes sometimes generate dramatic artefacts [4] , we consider heterologous expression in mammalian cell lines more reliable. But even with cell lines, binding of radiotracer to the expressed protein may be misinterpreted as uptake. Indeed, with other SLC22 transporters we have been unable to confirm suggested transport activities in several instances [5] [6] [7] . Since OAT2 is not closely related in amino acid sequence to OAT1 (40 % identity among human sequences), the function could be quite different.
On the whole, to us and others [3] , the physiological function of the hepatic carrier OAT2 was unsettled.
Previously, OAT2 from human was reported to catalyse the uptake of cGMP and 2 -deoxyguanosine [8] ; however, OAT2 from the rat does not transport these compounds (see the Results section). We thus have used the strategy of LC (liquid chromatography)-MS difference shading [9] in the present study to initiate a search for specific and cross-species substrates of OAT2.
In this method, lysates of cells with or without transporter expression are analysed by full-scan LC-MS. Two greyscale images with axes of m/z and time are generated in which the lowest intensities are rendered black [RGB (red green blue) model: 0, 0, 0] and the highest intensities are rendered white (255, 255, 255). Finally, a difference image is created, combining for each pixel the red component from the transporter active image with green and blue from the transporter inactive image. Thus compounds only present in the active data set can be spotted as red signals (e.g. 64, 0, 0), whereas compounds present in equal amounts in both sets remain scales of grey (e.g. 100, 100, 100).
Materials and Methods

Plasmid constructs
The cDNAs of OAT2h (human OAT2), OAT2r (rat OAT2), OAT1h (human OAT1) and the cDNA encoded by the human Abbreviations used: EAAT, excitatory amino-acid transporter; eGFP, enhanced green fluorescent protein; HEK, human embryonic kidney; LC, liquid chromatography; LCM, laser capture microdissection; MS/MS, tandem MS; N, negative; OAT, organic anion transporter; OAT1h, human OAT1; OAT2h, human OAT2; OAT2r, rat OAT2; P, positive; PAH, p-aminohippuric acid. 1 Present address: Institute for Cardiovascular Physiology, Faculty of Medicine, Goethe-University, Theodor-Stern-Kai 7, 60596 Frankfurt, Germany. 2 To whom correspondence should be addressed (email dirk.gruendemann@uni-koeln.de).
SLC22A13 gene were generated by RT (reverse transcription)-PCR, cloned into pUC19, fully sequenced and inserted into expression vector pEBTetD. pEBTetD is an episomal Epstein-Barr plasmid vector for doxycycline-inducible protein expression in human cell lines based on the simple tetracycline repressor [10] . The amino acid sequence of OAT2h corresponds to GenBank ® entry NM_006672. The 5 -interface between pEBTetD and cDNA is GTTTAAACTAAGCTTGCCACC-ATGGGCTTTGAGGAG (polylinker in bold, cDNA underlined); the 3 -interface is GTCCAGAACTAACTCGAGCGATCGC. The amino acid sequence of OAT2r corresponds to GenBank ® entry NM_053537. The 5 -interface is GTTTAAACTTAAGCT-TGCCACCATGGGCTTCGAAGAC. The 3 -UTR (untranslated region) corresponds to GenBank ® entry L27651; the 3 -interface is CTTCCCGCAGCACTCGAGCGATCGC. The amino acid sequence of OAT1h corresponds to GenBank ® entry NM_153276. The 5 -interface is GTTTAAACTTAAGCTTGCCACC-ATGGCCTTTAATGAC; the 3 -interface is AATGGACTCTGA CTCGAGCGATCGC. The amino acid sequence of SLC22-A13h corresponds to GenBank ® entry NM_004256. The 5 -interface is GTTTAAACTTAAGCTTGCCACCATGGCTCAG-TTTGTC; the 3 -interface is AAGAGCTGGACCCTCGAG CGATCGC. The OAT2h mutant was generated with the QuikChange ® II Kit (Stratagene).
Cell culture
HEK (human embryonic kidney)-293 cells (A.T.C.C. CRL-1573), a transformed cell line derived from human embryonic kidney, were grown at 37
• C in a humidified atmosphere (5 % CO 2 ) in plastic culture flasks (Falcon 3112, Becton Dickinson). The growth medium was Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10 % fetal bovine serum (PAA Laboratories). The medium was changed every 2-3 days and the culture was split every 5 days.
Stably transfected cell lines were generated as reported previously [10] . As there is no integration of vector pEBTetD into the genome, clonal isolation of transfected cells is not necessary; we thus use cell pools rather than single cell clones. The cell culture medium always contained 3 μg/ml puromycin (PAA Laboratories) to ascertain the plasmid maintenance. To turn on protein expression, cells were cultivated for at least 20 h in regular growth medium supplemented with 1 μg/ml doxycycline (MP Biomedicals).
Transport assays
For the measurement of solute uptake, cells were grown in surface culture on 60-mm polystyrol dishes (Nunc) precoated with 0.1 g/l poly-L-ornithine in 0.15 M boric acid/NaOH, pH 8.4. Cells were used for uptake experiments at a confluence of at least 70 %. Uptake was measured at 37
• C. The uptake buffer contains 125 mmol/l NaCl, 25 mmol/l Hepes/NaOH (pH 7.4), 5.6 mmol/l ( + ) glucose, 4.8 mmol/l KCl, 1.2 mmol/l KH 2 PO 4 , 1.2 mmol/l CaCl 2 and 1.2 mmol/l MgSO 4 . In the glutamate efflux experiments, the uptake buffer without KH 2 PO 4 was used to avoid MS interference. After pre-incubation for at least 20 min in 4 ml of uptake buffer, the buffer was replaced with 2 ml of substrate in uptake buffer. The total substrate concentration, if not indicated otherwise, was 0.1 μmol/l for radiotracer assays and 10 μmol/l for unlabelled compounds [LC-MS/MS (tandem MS) quantification]. Incubation was stopped after 1 min by rinsing the cells four times each with 4 ml of ice-cold uptake buffer. Radioactivity was determined, after cell lysis with 0.1 % Triton X-100 in 5 mmol/l Tris/HCl (pH 7.4), by liquid scintillation counting. For LC-electrospray ionization-MS/MS analysis, cells were lysed with methanol and stored at − 20
• C. After centrifugation (1 min at 16 000 g at 20 • C) of thawed lysates, 100 μl of the supernatant was mixed with either 10 μl of unlabelled 1-methyl-4-phenylpyridinium iodide (0.5 ng/μl) or biphenyl-4-carboxylic acid (Sigma-Aldrich) as the internal standard. Of this mixture, 20 μl samples were analysed by LC-MS/MS on a triple quadrupole mass spectrometer (4000 Q TRAP, Applied Biosystems).
The following LC conditions were used. cGMP: Atlantis dC 18 column (particle size 5 μm, 3.0 mm × 100 mm; Waters); A, 10 mM formic acid; B, 10 mM formic acid in acetonitrile; gradient, 0.3 ml/min, 5 % B at 0 min, 5 % B at 2 min, 60 % B at 5 min, 5 % B at 7 min and stop at 10 min. Glutamate: Atlantis dC 18 For each analyte, the area of the intensity as a function of the time peak was integrated and divided by the area of the internal standard peak to yield the analyte-response ratio. Linear-calibration curves were constructed from at least six standards, which were prepared using control cell lysates as solvent. The analyte content of the sample was calculated from the analyte-response ratio and the slope of the calibration curve.
For LC-MS quantification, the solute content of cell lysates was determined for four conditions (paired dishes, incubation time 1 min): (a) transporter expression on, uptake buffer; (b) expression off, uptake buffer; (c) expression on, substrate in uptake buffer; and (d) expression off, substrate in uptake buffer. Acute uptake mediated by heterologously expressed carrier was then calculated as (c − a) − (d − b). This approach takes into account endogenous solute content and non-specific uptake.
Protein was measured by the BCA (bicinchoninic acid) assay (Pierce) with BSA as a standard. The protein content of MS samples was estimated from three matched cell dishes.
Expression profiling and LCM (laser capture microdissection)
OAT2h mRNA was quantified by real-time PCR [7] ; a PCR reaction (20 μl 
For LCM, rat liver sections (16 μm) were prepared using a cryostat at − 20
• C and mounted on RNase-free PEN (polyethylene naphthalate)-membrane slides (Leica Microsystems). Sections were dried briefly at room temperature (20 • C), fixed in 75 % and 100 % ethanol (cooled to − 20
• C) for 15 s each, and stained with Weigert's iron haematoxylin followed by alcoholic eosin Y solution (Sigma-Aldrich). The rats were anaesthetized with isoflurane and killed by exsanguination. These procedures conformed with the American Veterinary Medical Association guidelines on euthanasia. A Leica DM6000B LMD system (Leica Microsystems) was used to isolate circular periportal and pericentral areas (average area = 0.02 mm 2 ). RNA was isolated from the captured discs using the RNeasy Plus Micro Kit (Qiagen). RNA integrity was verified using the Agilent 2100 bioanalyzer and RNA 6000 Pico LabChip Kit (Agilent Technologies). cDNA was generated with the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) and analysed by real-time PCR on a LightCycler 1.0 apparatus with system 2.0 software (Roche). Product accumulation was detected with locked nucleic acid hydrolysis probes (TaqMan principle) from the human Universal ProbeLibrary (Roche). A single reaction (total volume 10 μl) contained 1 μl of master mix (5 × concentration; LightCycler TaqMan Master; Roche), 1 μmol/l each of forward and reverse primer, 50 nmol/l probe and 1 μl of cDNA. Contamination controls contained water instead of DNA. After enzyme activation (10 min, 95
• C), thermocycling consisted of 45 cycles of 10 s at 95
• C, 30 s at 55
• C, and 1 s at 72
• C; the velocity of temperature change was 20 • C/s. Fluorescence curves were analysed by non-linear simultaneous fitting as described previously [11] to yield the relative mRNA level; β-actin was used for normalization.
Calculations and statistics
The clearance equals initial rate of specific uptake (uptake mediated by expressed carrier) divided by substrate concentration; it is directly proportional to k cat /K m (k cat is the turnover number) and thus a valid measure of efficiency of transport (provided that the substrate concentration is much smaller than the respective K m ) [4, 12] . Specific uptake equals the total uptake minus uptake into control cells (non-specific uptake).
All results are given as the arithmetic mean + − S.E.M. with at least n = 3; all assays were at least performed twice, on separate days. Analysis of saturation curves has been reported previously [13] . K m values are given as geometric means with 95 % confidence intervals.
Chemicals
Unlabelled compounds were as follows: cGMP sodium salt (Sigma-Aldrich), 2 -deoxyguanosine monohydrate (SigmaAldrich), L-glutamic acid potassium salt monohydrate (SigmaAldrich), 1-methyl-4-phenylpyridinium iodide (Sigma-Aldrich), orotic acid monohydrate (Sigma-Aldrich), PAH (Fluka) and trigonelline hydrochloride (Fluka). All other chemicals were at least of analytical grade.
The radiotracers used were: L-glutamic acid (H-3, 2.2 kBq/pmol, ART-132; ARC), orotic acid (H-3, 0.47 kBq/pmol, MT-668; Moravek).
RESULTS
OAT2 from the rat transports neither cGMP nor 2 -deoxyguanosine cDNAs of OAT1h, OAT2h and OAT2r were inserted into the pEBTetD expression vector [10] and then stably transfected into HEK-293 cells. The initial rates of uptake (1 min, 37
• C) of cGMP and 2 -deoxyguanosine (each at 10 μmol/l) were determined with freshly dissolved unlabelled compounds by LC-MS/MS. OAT2h, in accordance with previous data [8] , catalysed the uptake of cGMP (transporter-mediated acute clearance = 48 + − 2 μl · min Figure S1) .
To verify that trigonelline is directly transported by OAT2 and not just increased indirectly, initial rates of uptake (1 min, 37
• C) of trigonelline (10 μmol/l) were determined by LC-MS/MS. The carrier-mediated clearance of trigonelline was 121 + − 5 μl · min − 1 · mg of protein − 1 for OAT2h, but only 4.8 + − 0.5 μl · min − 1 · mg of protein − 1 for OAT2r. Accumulation of trigonelline upon expression of OAT2 is carrier specific, since the related OAT1h and SLC22A13h were without effect (results not shown). Orotic acid is an excellent and specific substrate of OAT2 from rat and human
To search for better substrates of OAT2r, compounds related in structure to trigonelline were assayed. In 1 min uptake experiments, no transport by OAT2r was observed with 2-aminobenzoic acid, 3-aminobenzoic acid, 4-aminobenzoic acid, 5-aminolevulinic acid, creatine, guanidinoacetic acid, L-proline, riboflavin, stachydrine and thiamine. However, orotic acid was transported with high efficiency (Figure 1A) by OAT2r (clearance = 106 + − 4 μl · min A time course ( Figure 1B ) with 10 μmol/l unlabelled orotic acid in uptake buffer revealed that OAT2r elevates intracellular orotic acid, selectively measured by LC-MS/MS, to a plateau of 5.8 nmol/mg of protein after 60 min; this corresponds to 870 μmol/l (calculated with an intracellular water space of 6.7 μl/mg of protein [14] ). In contrast, cells lacking the transporter reached only 0.05 nmol/mg of protein after 60 min. The clearance (k in ) was increased from 0.58 + − 0.12 to 50.1 + − 6.4 μl · min − 1 · mg of protein − 1 by expression of OAT2r, i.e. by a factor of 86. Saturation analysis of OAT2r-mediated uptake of [ 3 H]orotic acid ( Figure 1C ) revealed a K m of 200 (95 % confidence interval: 160 -240) μmol/l, which for a transport protein indicates moderate affinity.
Efflux of glutamate drives uptake of orotic acid
If OAT2r simply facilitated diffusion, then the monoanion orotic acid (pK a ≈ 2.4 [15] ) should only accumulate, at regular membrane potential and 10 μmol/l extracellular, to approximately 1 μmol/l intracellularly. What is the force driving accumulation of orotic acid up to 870 μmol/l (see above)? Full replacement of sodium chloride in the uptake buffer by choline chloride, lithium chloride or potassium chloride, or complete omission of magnesium and calcium reduced uptake of orotic acid only 
H]orotic acid via OAT2r by potential substrates
OAT2r-expressing cells in dishes were incubated (1 h at 37 • C) with 100 μmol/l [ 3 H]orotic acid in uptake buffer, washed twice with ice-cold uptake buffer and then incubated for 1 min with uptake buffer (control) or 1 mmol/l of the indicated compounds in uptake buffer (1 ml). Finally, uptake buffer (0.7 ml) was collected and analysed by liquid-scintillation counting for released slightly, by a factor of 0.75 on average (results not shown); thus co-transport of inorganic cations was ruled out. Efflux of [ 3 H]orotic acid from preloaded cells into uptake buffer was measured (1 min) to identify compounds that can drive OAT2r. The assay was validated with unlabelled orotic acid (1 mmol/l) in uptake buffer, which markedly accelerated efflux ('trans-stimulation') over the control (Figure 2 ). Among several anionic candidate compounds, which are present in liver cells at substantial concentrations (>0.1 mmol/l) [16, 17] Figure 3A) . For a better signal-tonoise ratio, background uptake (OAT2r expression off), probably caused to a large part by an EAAT (excitatory amino-acid transporter)-type glutamate transporter endogenous to HEK-293 cells [18] , was reduced strongly with sodium-free uptake buffer or by addition of 1 mmol/l aspartate; the clearance of [16, 19] , the results of the present study suggest that OAT2 operates as a glutamate efflux transporter. To test this hypothesis, HEK-293 cells with or without expression of OAT2r were incubated for 10 min in uptake buffer; then, the glutamate content of a buffer sample was determined by LC-MS/MS. Expression of OAT2 markedly increased release of glutamate from cells, even without extracellular exchange substrate ( Figure 3B, control buffer) . Addition of 1 mmol/l aspartate blocked the endogenous EAAT-type glutamate uptake transporter and thus revealed even higher glutamate efflux. Addition of 1 mmol/l orotic acid strongly trans-stimulated efflux of glutamate. As a consequence of continuous efflux, the intracellular glutamate content was clearly reduced in HEK-293 cells expressing OAT2r (f = 0.55 + − 0.11; n = 4) or OAT2h (f = 0.60 + − 0.09; n = 2) compared with uninduced control cells (calculated by f = glutamate content of OAT2-expressing cells/glutamate content of control cells).
A negative charge in transmembrane segment 10 of OAT2 is critical for glutamate transport
In transmembrane segment 10, the OAT2 orthologues from human, horse, pig, cattle, rabbit, rat, mouse, opossum and chicken uniformly contain a glutamate residue (Glu 441 in OAT2h) that is absent in the related carriers OAT1, OAT3 and SLC22A13. Since in other SLC22 family members transmembrane segment 10 is involved in substrate discrimination [20] , the negative charge of the glutamate side chain could specifically attract the ammonium cation of the glutamate substrate. To test this hypothesis, a mutant of OAT2h was created with glutamine residue at position 441 (E441Q); eGFP (enhanced green fluorescent protein) was attached to the C-terminus to verify unaltered membrane trafficking (Supplementary Figure S3 at http://www.BiochemJ. org/bj/436/bj4360305add.htm). With the mutant, uptake of [ 3 H]glutamate was completely abolished ( Figure 4) ; by contrast, uptake of [ 3 H]orotic acid was much reduced, but still evident. This reduction probably reflects the loss of driving force (glutamate efflux) rather than reduced orotic acid transport competence. Our results thus suggest that the OAT2h mutant E441Q is folded and Results are given relative to the mRNA level of liver. The following tissues or cells had a signal <0.1 %: cerebellum, brain, ovary, HEK-293 cells, spleen, prostate, skin, heart, pancreas, leucocytes (peripheral), skeletal muscle, bone marrow, lung and placenta. (B) Hepatic zonation of OAT2r analysed by LCM followed by real-time PCR. Periportal and pericentral tissue discs were isolated from male rat liver slices; random areas on the same sections were used as control ('total liver'). Results for each mRNA species were scaled to the material with the highest content (which is taken to be 100 % for the calculation of the relative values). Note that OAT2 results were confirmed with a second amplicon (results not shown). Similar results were obtained with two further male rats.
sorted like the wild-type carrier. It follows that Glu 441 is essential for transport of glutamate.
Localization of OAT2
The tissue distribution of OAT2 from humans was analysed by quantitative real-time RT-PCR ( Figure 5A ). The highest mRNA content was detected in the liver and fetal liver (30 %); liver contained >10-fold more OAT2 mRNA than kidney (8.5 %), >100-fold more than testis, ileum and uterus, and >1000-fold more than all other tissues or cells tested (see legend of Figure 5 ).
The zonal distribution of OAT2 in liver is unknown. We used LCM of rat liver slices followed by real-time PCR to probe expression in periportal and pericentral (perivenous) acinus regions. Glutaminase 2 and glutamine synthetase served as controls; the results ( Figure 5B ) indicate excellent region-specific separation of captured cell discs. OAT2r mRNA was detected equally in both regions.
DISCUSSION
Our results demonstrate that OAT2 (human gene name SLC22A7) can catalyse both uptake and efflux of glutamate. However, since glutamate is the most abundant intracellular amino acid (reported concentrations, including hepatocytes, range from 2-20 mmol/l [21] ), OAT2 effectively operates as a glutamate efflux carrier. Notably, even without any extracellular exchange substrate, the carrier releases glutamate from cells (see Figure  3B ). The moderate affinity (K m OAT2r = 1.2 mmol/l; measured as uptake) reflects that the purpose of OAT2 is not to collect glutamate from the extracellular space, but to provide an exit passage for intracellular cytosolic glutamate. As the intracellular glutamate concentration is higher than the K m , strong efflux is generated nevertheless. The benefit of lower-thanpossible glutamate transport efficiency (24-70 μl · min − 1 · mg of protein − 1 ) is supreme substrate selectivity: OAT2 rejects other abundant intracellular anions such as lactate, malate, 2-oxoglutarate and even the extremely similar aspartate (Figure 2) . In striking contrast, the high-affinity sodium-driven EAAT-type glutamate uptake transporters all move aspartate and glutamate equally well [22] . Thus our results suggest that the general physiological purpose of OAT2 is to release glutamate from cells. This function, as expected for a fundamental feature, is conserved over species: human, rat (the present study), pig and mouse (C. Fork, N. Himmelreich and D. Gründemann, unpublished work). Since the related carriers OAT1, OAT3 and SLC22A13 do not transport glutamate but 2-oxoglutarate, OAT2 is unique within the SLC22 family. The specific function depends on conserved amino acids such as Glu 441 ( Figure 4 ). Our real-time PCR data indicate that OAT2h is primarily expressed in the liver; the only other noteworthy tissue is the kidney, at merely 8.5 % relative to the liver ( Figure 5A ). Similar results were obtained for rat (results not shown). To investigate the zonal distribution of OAT2 in rat liver, we have raised two polyclonal antibodies targeted at the peptides TEVSNSGEPEGEPLTV and KLNGRPVGEGSLSQE; these generated no specific signals however (results not shown). Our LCM results ( Figure 5B ) suggest that expression of OAT2r is homogenous across hepatocytes, confined neither to periportal (glutaminase 2 marker) nor to pericentral (glutamine synthetase marker) regions.
If the assignment of OAT2 as a hepatic glutamate efflux transporter is correct, then there should be a corresponding phenotype. Indeed, release of glutamate from liver into the blood has been reported: in rats fed a protein-free diet, glutamate was released at 64 μmol/l as calculated by the plasma concentration difference between portal vein and hepatic vein [23] ; isolated perfused rat liver continuously (observation time of 100 min) released glutamate at a rate of 40-60 nmol · min − 1 · g − 1 [24, 25] , with this export being sodium independent; and under diets either slightly deficient (11 % casein) or moderately surfeit (22 % casein) in protein, glutamate and glutamine were markedly released by rat liver [26] . Collectively, these observations can now be explained by OAT2 activity and thus reinforce the hypothesis that OAT2 functions as a hepatic glutamate efflux transporter. Moreover, with isolated perfused rat liver both periportal [24] and pericentral [27] release of glutamate was observed; this conforms to our LCM data on OAT2r.
The extent of hepatic release of glutamate was documented further by recent experiments with pigs. In a model of acute liver failure induced by portacaval shunt and hepatic artery ligation, the arterial glutamate concentration was reduced 6-fold 2 h after induction (67 compared with 416 μmol/l) [28] . A marked decrease in plasma glutamate was also measured c The Authors Journal compilation c 2011 Biochemical Society in patients with liver failure [29, 30] , cirrhosis [29] and acute chronic liver disease [29, 30] . Moreover, patients who die of septic shock with acute liver dysfunction can be predicted by significantly lowered plasma glutamate concentrations and lowered glutamate/glutamine ratios [31] . Thus the liver, via OAT2 as we can now suggest, maintains glutamate levels in plasma; glutamate absorbed from food normally has no role here, since it is metabolized in the intestine and released primarily as alanine [23] . It follows that plasma glutamate depletion is a feature of liver failure like loss of ureagenesis.
Transport of glutamate is the primary, but not the only, catalytic function of OAT2. The steep outwardly directed glutamate gradient (see above) provides a powerful driving force for the uptake of selected solutes. We have discovered orotic acid as an outstanding and specific substrate of OAT2. Orotic acid is an intermediate in pyrimidine biosynthesis and a natural dietary constituent (e.g. in dairy products and root vegetables) [32] . Orotic acid transport proteins have been identified in bacteria [33] , but not in mammals. Rat liver absorbs orotic acid rapidly [34] . However, since orotic acid is not retained, but efficiently eliminated by the kidney [35] , a physiological demand for hepatic uptake of orotic acid seems unlikely at present. Still, in diseases that cause orotic aciduria [32] , OAT2 could serve as an exit passage for the large amounts of orotic acid generated in hepatocytes. In humans, there is capacity for hepatic uptake of trigonelline, cGMP, deoxyguanosine [8] or uric acid [36] , but the physiological relevance is doubtful.
Could OAT2 become a target for therapeutic intervention? One option is the development of a specific efflux blocker, which should markedly lower plasma glutamate. This could be useful to alleviate glutamate exotoxicity in the central nervous system. Glutamate is the major excitatory neurotransmitter in the vertebrate CNS, but excessive extracellular glutamate is highly toxic to neurons. Some of the glutamate is cleared by brainto-blood efflux [37] ; a reduction of plasma glutamate promotes this efflux [38] . Thus reduction of plasma glutamate may have important implications in the treatment of acute brain conditions, including closed head injury and stroke [39] . A reduction can be achieved by infusion of substrates of glutamate-oxaloacetate transaminase or glutamate-pyruvate transaminase [40] . However, inhibition of OAT2 could be a superior alternative. Another option for therapeutic intervention would be to increase glutamate efflux via OAT2, e.g. by infusion of orotic acid. This could compensate the loss of plasma glutamate described above in liver failure. Indeed, infusion of glutamate has been successfully used in coma patients with liver failure [41] . Administration of L-ornithine plus L-aspartate also aims to increase glutamate availability for glutamine synthesis to lower ammonia, e.g. in hepatic encephalopathy [28, 42] .
In conclusion, we have uncovered that OAT2 from human and rat efficiently transport orotic acid and glutamate. Based on functional features and localization data, we propose that OAT2 physiologically functions as a glutamate efflux transporter in all hepatocytes. Previous reports of hepatic release of glutamate into blood can now be explained by OAT2 activity. A specific OAT2 inhibitor could, by lowering plasma glutamate and thus promoting brain-to-blood efflux of glutamate, alleviate glutamate exotoxicity in acute brain conditions.
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